Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

NASDAQHealthcareMedical - Care Facilities

Previous close

$13.16

+$0.19 · +1.46%

Aug 21, 4:00 PM ET

AVAH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

80

Undervalued

Momentum

59

Neutral

Sentiment

45

Mixed

Risk resilience

58

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Aveanna Healthcare Holdings Inc. operates as a diverse platform for home-based care services throughout the United States. The company delivers a range of critical offerings, including private duty nursing (PDN), adult home health and hospice care, in-home pediatric therapy, and enteral nutrition services. Its patient-centered approach allows individuals to receive essential medical care within their own homes, effectively reducing the need for costly institutional settings such as hospitals. The company's operations are structured into three key segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment provides specialized private duty nursing, which includes skilled nursing care for medically fragile children at home, nursing support in school environments, and services at pediatric day healthcare centers. This segment also offers employer-of-record support, personal care services, and pediatric therapy (physical, occupational, and speech) provided both in clinics and patients' residences. The HHH segment focuses on home health services, encompassing in-home skilled nursing, physical, occupational, and speech therapy, as well as medical social work and aide assistance. Furthermore, it delivers hospice services, offering compassionate care to patients and their families when life-limiting illnesses no longer respond to curative treatments. The MS segment supplies enteral nutrition products and other vital medical supplies to adults and children, distributed on either a scheduled or as-needed basis. Founded in 2016, Aveanna Healthcare Holdings Inc. is headquartered in Atlanta, Georgia.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
Jeffrey S. Shaner
Listed since
Apr 28, 2021
Employees
35,500

Market position

Day range

Current $13.16

52-week range

Current $13.16

Open
$12.82
Previous close
$12.97
Volume
8.42M
3.8× average
Average volume
2.21M
Average daily volume
Market cap
2.87B USD
Beta
1.93
Market reference 1
50-day average
$9.5226
+38.20% above average
200-day average
$8.1827
+60.83% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.97B USD
P/E (TTM)
9.91×
P/B (TTM)
9.98×
P/S (TTM)
1.1×
EV / EBITDA
10.8×
Earnings yield
13.68%
Free cash flow yield
6.98%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
31.95%
Operating margin
11.12%
Net margin
10.56%
Return on equity
115.72%
Return on assets
11.11%
Return on invested capital
14.73%

Financial health

Debt / equity
5.24×
Current ratio
1.32×
Altman Z-score
1.94
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends40%12%-16%-44%Gross margin, FY2021: 32.31%Gross margin, FY2022: 30.95%Gross margin, FY2023: 31.42%Gross margin, FY2024: 31.39%Gross margin, FY2025: 33.09%Operating margin, FY2021: -2.15%Operating margin, FY2022: -35.93%Operating margin, FY2023: 0.43%Operating margin, FY2024: 6.90%Operating margin, FY2025: 10.91%Net margin, FY2021: -6.97%Net margin, FY2022: -37.03%Net margin, FY2023: -7.10%Net margin, FY2024: -0.54%Net margin, FY2025: 9.25%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 32.31%. Gross margin FY2022 30.95%. Gross margin FY2023 31.42%. Gross margin FY2024 31.39%. Gross margin FY2025 33.09%. Operating margin FY2021 -2.15%. Operating margin FY2022 -35.93%. Operating margin FY2023 0.43%. Operating margin FY2024 6.90%. Operating margin FY2025 10.91%. Net margin FY2021 -6.97%. Net margin FY2022 -37.03%. Net margin FY2023 -7.10%. Net margin FY2024 -0.54%. Net margin FY2025 9.25%.

Income trends

Revenue

2.43B USD+20.19%

Operating income

265.38M USD+89.85%

Net income

225.03M USD+235.96M USD
Income trends across reported periods2.74B USD1.5B USD266.54M USD−971.56M USDRevenue, FY2021: 1.68B USDRevenue, FY2022: 1.79B USDRevenue, FY2023: 1.9B USDRevenue, FY2024: 2.02B USDRevenue, FY2025: 2.43B USDOperating income, FY2021: −36.11M USDOperating income, FY2022: −642.28M USDOperating income, FY2023: 8.07M USDOperating income, FY2024: 139.79M USDOperating income, FY2025: 265.38M USDNet income, FY2021: −117.04M USDNet income, FY2022: −662.03M USDNet income, FY2023: −134.52M USDNet income, FY2024: −10.93M USDNet income, FY2025: 225.03M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.68B USD. Revenue FY2022 1.79B USD. Revenue FY2023 1.9B USD. Revenue FY2024 2.02B USD. Revenue FY2025 2.43B USD. Operating income FY2021 −36.11M USD. Operating income FY2022 −642.28M USD. Operating income FY2023 8.07M USD. Operating income FY2024 139.79M USD. Operating income FY2025 265.38M USD. Net income FY2021 −117.04M USD. Net income FY2022 −662.03M USD. Net income FY2023 −134.52M USD. Net income FY2024 −10.93M USD. Net income FY2025 225.03M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.43B USD2.02B USD1.9B USD1.79B USD1.68B USD
Cost of goods sold1.63B USD1.39B USD1.3B USD1.23B USD1.14B USD
Gross profit805.15M USD635.54M USD595.43M USD553.23M USD542.4M USD
Selling, general, and administrative526.74M USD470.47M USD464.74M USD483.95M USD419.64M USD
Operating expenses539.77M USD495.76M USD587.36M USD1.2B USD578.52M USD
Interest income2.83M USD498K USD327K USD679K USD253K USD
Interest expense140.09M USD156.6M USD153.25M USD107.72M USD68.93M USD
Depreciation and amortization23.77M USD31.16M USD30.1M USD38.82M USD35.39M USD
Operating income265.38M USD139.79M USD8.07M USD−642.28M USD−36.11M USD
Net income225.03M USD−10.93M USD−134.52M USD−662.03M USD−117.04M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+218.79%
11 comparable reports
Latest EPS result
0.22
Estimate 0.17 · Beat by 30.72%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.260.170.090Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual 0.05, estimate 0.004, surprise +1178.77%, Beat. Q2 2025, reported May 8, 2025: actual 0.1, estimate 0.032, surprise +216.76%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.18, estimate 0.04, surprise +350.00%, Beat. Q4 2025, reported Nov 6, 2025: actual 0.15, estimate 0.08, surprise +87.50%, Beat. Q1 2026, reported Mar 19, 2026: actual 0.17, estimate 0.154, surprise +10.53%, Beat. Q2 2026, reported May 14, 2026: actual 0.18, estimate 0.13, surprise +38.46%, Beat. Q3 2026, reported Aug 13, 2026: actual 0.22, estimate 0.168, surprise +30.72%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.18, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates704.25M632.53M560.81M489.09MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual 519.87M USD, estimate 516.17M USD, surprise +0.72%, Beat. Q2 2025, reported May 8, 2025: actual 559.22M USD, estimate 527.28M USD, surprise +6.06%, Beat. Q3 2025, reported Aug 7, 2025: actual 589.55M USD, estimate 540.24M USD, surprise +9.13%, Beat. Q4 2025, reported Nov 6, 2025: actual 621.94M USD, estimate 649.48M USD, surprise -4.24%, Miss. Q1 2026, reported Mar 19, 2026: actual 662.48M USD, estimate 643.03M USD, surprise +3.02%, Beat. Q2 2026, reported May 14, 2026: actual 647.92M USD, estimate 613.22M USD, surprise +5.66%, Beat. Q3 2026, reported Aug 13, 2026: actual 670.48M USD, estimate 638.61M USD, surprise +4.99%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 677.16M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings
Strong buy18%
Buy650%
Hold433%
Sell18%
Strong sell00%

AVAH news

AVAH peers

ETFs holding AVAH

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research AVAH

research.disclaimer